Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro cardiac new approach methodologies predict clinical cardiovascular repolarization risk comparable to non-clinical animal studies.

British journal of pharmacology·2026
Same author

Effect of Paroxetine or Escitalopram Coadministered with Oxycodone versus Oxycodone Alone on Ventilation during Hypercapnia: A Randomized Clinical Trial.

Anesthesiology·2026
Same author

Nonclinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination.

NAM journal·2026
Same author

Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study.

Frontiers in drug discovery·2025
Same author

Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects.

Clinical and translational science·2025
Same author

Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential.

Journal of cardiovascular development and disease·2025

Related Experiment Video

Updated: Mar 11, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.2K

Clinical Trials in a Dish.

David G Strauss1, Ksenia Blinova2

  • 1Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.

Trends in Pharmacological Sciences
|November 24, 2016
PubMed
Summary
This summary is machine-generated.

Clinical trials in a dish use human tissue in labs to test medical therapies. Advances in biotechnology are enabling these new drug safety assessment methods, with the FDA supporting their development.

More Related Videos

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
08:43

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models

Published on: January 14, 2020

12.0K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K

Related Experiment Videos

Last Updated: Mar 11, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.2K
Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
08:43

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models

Published on: January 14, 2020

12.0K
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
12:41

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on: December 23, 2022

5.9K

Area of Science:

  • Biotechnology
  • Drug Development
  • Regulatory Science

Background:

  • Clinical trials in a dish utilize human tissue for in vitro drug testing.
  • Recent advances in induced pluripotent stem cells, organs-on-a-chip, and whole-genome sequencing enable these complex models.
  • These 'in a dish' systems offer novel approaches to assess therapeutic safety and efficacy.

Purpose of the Study:

  • To provide an overview of the current landscape of clinical trials in a dish.
  • To highlight the U.S. Food and Drug Administration's (FDA) initiatives in this field.
  • To support the development and validation of new regulatory paradigms for drug safety assessment.

Main Methods:

  • Review of current biotechnology advancements.
  • Analysis of FDA's strategic steps and support for novel regulatory approaches.
  • Overview of the scientific principles behind 'in a dish' clinical trials.

Main Results:

  • The scientific field of clinical trials in a dish is rapidly advancing.
  • The FDA is actively engaged in fostering the science and regulatory acceptance of these technologies.
  • New paradigms for drug safety assessment are emerging based on these laboratory models.

Conclusions:

  • Clinical trials in a dish represent a significant shift in preclinical drug evaluation.
  • Continued development and validation are crucial for integrating these methods into regulatory drug approval processes.
  • The FDA's commitment is key to advancing the use of these innovative technologies for ensuring drug safety.